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Background: The prognostic utility of systemic inflammatory markers has so far not been investigated in patients with metastatic
testicular germ cell tumours (GCTs).
Methods: International Germ Cell Cancer Cooperative Group (IGCCCG) risk groups and blood-based systemic inflammatory
markers (haemoglobin, leukocytes, platelets (P), neutrophils (N), lymphocytes (L), C-reactive protein (CRP) and albumin) of 146
patients undergoing first-line chemotherapy for GCT were retrieved. In addition, N to L ratio (NLR), P to L ratio and the systemic
immune-inflammation index (SII¼N P/L) were calculated. The prognostic ability of these markers for overall survival (OS) were
assessed using regression analyses and Kaplan–Meier curves with log-rank tests.
Results: In univariate Cox regression, low haemoglobin and albumin as well as high leukocytes, N, NLR, SII and CRP were
associated with a shorter OS. In multivariable Cox regression analyses, high leukocyte (hazard ratio (HR) 1.274 (95% confidence
interval (CI) 1.057–1.535); P¼ 0.011) and N count (1.470 (1.092–1.980); P¼ 0.011), higher NLR (84.5 (2.2–3193.4); P¼ 0.017) and SII
(12.15 (1.17–126.26); P¼ 0.037) remained independent prognostic predictors for OS besides the IGCCCG risk groups.
Conclusions: Systemic inflammatory markers might have prognostic utility for patients with metastatic GCT. The planned IGCCCG
update could be an opportunity to test these markers in a larger data set.
An estimated number of 8850 new cases of germ cell tumours
(GCTs) will be diagnosed in the United States in 2017 (Siegel et al,
2017). Thirty percent of all patients present with metastases at
initial diagnosis (DeSantis et al, 2014). An additional 15–30%
develop metastatic disease recurrence during follow-up (Daugaard
et al, 2014; Chung et al, 2015). Although metastatic GCTs usually
respond very well to cisplatin-based chemotherapy, 10–15% of
patients fail first-line treatment and 3–5% of all GCT patients will
eventually die of their disease (Gandaglia et al, 2014).
In 1997, the International Germ Cell Cancer Cooperative Group
(IGCCCG) published a prognostic classification system for patients
with metastatic GCT, which is currently used to determine the
treatment algorithm for these patients (International-Germ-Cell-
Cancer-Collaborative-Group, 1997). The histological subtype
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(seminoma vs non-seminoma), the location of the primary tumour,
the extent of metastatic spread as well as the level of the tumour
markers alpha-fetoprotein (AFP), beta-human chorionic gonado-
tropin (HCG) and lactate dehydrogenase (LDH) are used in this
classification system, which divides patients with metastases into
groups of either good, intermediate or poor risk.
Inflammation is known to play an important role in the biology
of many tumours and is considered a hallmark of cancer
(Grivennikov and Karin, 2010; Hanahan and Weinberg, 2011).
Several markers of systemic inflammation (e.g., leucocytes,
neutrophils, thrombocytes) can be obtained from routine blood
tests such as the complete blood count (CBC). Some of these
markers and particularly ratios of different markers have been
shown to be of prognostic value in various malignancies including
genitourinary cancers such as urothelial cancer, kidney cancer and
prostate cancer (Yamanaka et al, 2007; Sarraf et al, 2009; Azab
et al, 2012; Ishizuka et al, 2013; Hermanns et al, 2014; Templeton
et al, 2014b; Bhindi et al, 2016). However, the prognostic utility of
different systemic inflammatory markers for patients with
testicular cancer has yet to be elucidated.
For patients with metastatic GCTs, inflammatory markers could
add prognostic information to the well-established IGCCCG
prognostic system. Thus, the aim of the present investigation was
to assess whether different inflammatory markers obtained from
routine blood tests are independent predictors of oncologic
outcome besides the IGCCCG prognostic system.
PATIENTS AND METHODS
We identified patients who underwent first-line chemotherapy for
metastatic GCT at our institution between 2000 and 2015. We
excluded patients with extragonadal GCT, bilateral testicular GCT,
missing systemic inflammatory markers or missing follow-up
information. Pre-chemotherapy baseline characteristics (age, body
mass index, histology of the primary tumour, TNM stage and
IGCCCG risk groups) and results from routine pre-chemotherapy
blood tests were retrieved from our electronic medical records.
Blood tests included the tumour markers AFP, HCG and LDH.
Furthermore CBC-based systemic inflammatory markers such as
haemoglobin, platelets (P), leukocytes, lymphocytes (L), and
neutrophils (N) as well as non-CBC markers (C-reactive protein
(CRP) and albumin) were extracted. In addition, the neutrophil-to-
lymphocyte ratio (NLR), the platelet-to-lymphocyte ratio (PLR)
and the systemic immune-inflammation index (SII; NP/L) were
calculated. The survival status of the patients was identified from
death certificates or medical charts. The overall survival (OS) was
measured from the date of initial chemotherapy to the date of
death from any cause. Patients were censored at the date of last
follow-up. The local ethics committee approved the study protocol
and waived informed consent (STV KEK-ZH 25-2008).
We performed a univariate Cox regression analysis to assess the
association between IGCCCG risk groups, systemic inflammatory
markers and OS. Several multivariable Cox regression analyses
including IGCCCG risk groups and each individual systemic
inflammatory marker separately were performed to assess the
incremental prognostic information of each marker in addition to
the IGCCCG risk groups. Due to the low rate of events, we were
not able to perform a single multivariable regression analysis
including the IGCCCG risk groups and all relevant systemic
inflammatory markers. Systemic inflammatory markers in uni-
variate and multivariable analyses were evaluated as continuous
variables. AFP, HCG, LDH, NLR, PLR, SII and CRP were log-
transformed due to their skewed distribution.
Because clinical decision-making is facilitated by defined cutoff
values, we performed raw receiver operating curve (ROC) analyses
using the maximal Youden’s index (¼ sensitivityþ specificity 1)
(Youden, 1950) to determine an optimal cutoff value. Kaplan–
Meier analyses with log-rank tests were used to compare survival
outcomes between patients with systemic inflammatory markers
above vs below the optimal cutoff point.
To assess whether more advanced disease is associated with
higher values of the systemic inflammatory markers in patients
with metastatic GCTs, a subgroup analysis comparing patients
with or without brain, bone and visceral metastases was performed.
Statistical analyses were performed using SPSS Statistics version
21.0 (IBM Corp., Armonk, NY, USA). The results for continuous
normally distributed variables are expressed as mean±s.d.
Continuous non-normally distributed variables are presented as
median and interquartile ranges (IQRs) and categorical variables
are presented as percentage. All P-values o0.05 were considered
statistically significant. All statistical tests were two-sided.
RESULTS
The baseline characteristics of all 146 patients are summarised in
Table 1. Thirty-seven patients presented with seminoma and 108
patients with non-seminoma. Sixty-one patients (42%) were
classified as clinical stage II and 85 patients (58%) as clinical stage
III. Ninety-seven patients (66%) were classified as IGCCCG good
risk, 26 patients (18%) as intermediate and 23 patients (16%) as
poor risk. Median follow-up was 53 months (IQR: 23–91 months).
After first-line chemotherapy response evaluation was available in
130 patients. Complete remission was achieved in 49 patients
(38%), partial remission in 55 patients (42%), stable disease in two
patients (2%) and progressive disease in three patients (2%).
Retroperitoneal lymph-node dissection was performed in 21 non-
seminoma patients because of a post-chemotherapy residual mass.
Overall, 42 patients (29%) progressed or relapsed after first-line
chemotherapy. Twenty-eight of these patients (67%) received
salvage chemotherapy, 11 patients (26%) underwent surgical
resections of metastases in the lung (n¼ 6), liver (n¼ 2) or non-
retroperitoneal lymph-nodes (n¼ 3) and 4 patients (10%)
underwent radiotherapy. A total of 17 patients (12%) died during
follow-up.
In univariate Cox regression analysis, low-serum haemoglobin
(hazard ratio (HR) 0.962 (95% confidence interval (CI)¼ 0.942–
0.982); Po0.001) and low albumin levels (HR: 0.844 (95%
CI¼ 0.742–0.961); P¼ 0.010) as well as elevated leukocytes (HR
1.136 (95% CI¼ 1.141–1.565); Po0.001) or neutrophils (HR:
1.611 (95% CI¼ 1.232–2.105); Po0.001) as well as a higher NLR
(HR per 10-fold increase: 73.05 (95% CI 3.70–1442.25); P¼ 0.005),
a higher SII (HR per 10-fold increase: 30.20 (95% CI¼ 3.00–
304.21); P¼ 0.004) and a higher CRP (HR 6.44 (95% CI¼ 2.04–
20.29); P¼ 0.001) were associated with a shorter OS (Table 2). A
significant association of platelet and lymphocyte counts or PLR
with OS could not be detected.
In multivariable analyses that included one individual systemic
inflammatory marker and the IGCCCG risk groups leukocyte
count (HR per 10-fold increase: 1.274 (95% CI¼ 1.057–1.535);
P¼ 0.011), neutrophil count (HR per 10-fold increase: 1.470 (95%
CI¼ 1.092–1.980); P¼ 0.011), NLR (HR per 10 increase: 84.5
(95% CI¼ 2.2–3193.4); P¼ 0.017) and SII (HR per 10 increase:
12.15 (95% CI¼ 1.17–126.26); P¼ 0.037) remained independent
predictors of OS besides the IGCCCG risk groups. Haemoglobin,
CRP and albumin could not be confirmed as independent
prognostic variables (see Table 3).
In order to define cutoff values for clinical decision-making
ROC analyses revealed ideal cutoff points for leukocytes at 11.6 103
per ml (AUC 0.755 (95% CI 0.602–0.908); P¼ 0.006), for
neutrophils at 5.1 103 per ml (AUC 0.755 (95% CI 0.633–0.917);
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P¼ 0.005), for NLR at 4.5 (AUC 0.811 (95% CI 0.693–0.930);
P¼ 0.001) and for SII at 1428 (AUC 0.797 (95% CI 0.646–0.947);
P¼ 0.002). Kaplan–Meier curves and log-rank tests confirmed that
high leukocyte and neutrophil counts as well as high NLR and SII
were associated with worse prognosis (all Po0.001) (Figure 1).
A subgroup analysis comparing inflammatory markers between
patients with to patients without brain, bone and visceral
metastases revealed significantly higher levels of leukocytes (8.9
vs 6.8 103 per ml, Po0.01) and neutrophils (7.1 vs 4.5 103 per ml,
Po0.01) but no significant differences for NLR (P¼ 0.062) or SII
(P¼ 0.057).
DISCUSSION
The majority of patients diagnosed with metastatic GCT can be
cured due to highly effective chemotherapy treatments. Using the
IGCCCG classification, patients can be allocated into three risk
groups that are widely used to determine the intensity of systemic
first-line treatment. However, despite IGCCCG risk prediction and
potent chemotherapy regimens, a subset of patients still fails first-
line chemotherapy and some of those patients eventually die from
their disease. Identification of these high-risk patients could trigger
Table 1. Baseline characteristics
N¼146
Age (years) (±SD) 34 (9)
BMI (kg cm 2) (±SD) 25 (5)
Seminoma n (%) 37/146 (25%)
Non-seminoma n (%) 108/146 (74%)
Unknown n (%) 1/146 (o1%)
Clinical stage
Stadium II n (%) 61/146 (42%)
Stadium III n (%) 85/146 (58%)
IGCCCG risk groups
Good risk n (%) 97/146 (66%)
Intermediate risk n (%) 26/146 (18%)
Poor risk n (%) 23/146 (16%)
Site of metastases








AFP (mg l1) (IQR) 5.70 (2.75–143.50)
HCG (U l1) (IQR) 7.70 (0.0–1021.1)
LDH (U l1) (IQR) 445 (324–771)
Haemoglobin (g l1) (IQR) 146 (133–157)
Leukocytes (103 per ml) (±SD) 7.54 (2.61)
Thrombocytes (103 per ml) (±SD) 289 (100)
Neutrophils (103 per ml) (±SD) 5.08 (2.10)
Lymphocytes (103 per ml) (±SD) 1.47 (0.52)
CRP (mg l1) (IQR) 5.00 (1.00–20.25)
Albumin (IQR) 43 (39–46)
NLR (IQR) 3.18 (2.34–5.07)
PLR (IQR) 182 (133–167)
SII (IQR) 898 (511–1520)
Abbreviations: AFP¼ alpha-fetoprotein; HCG¼beta-human chorionic gonadotropin;
BMI¼body mass index (kg cm 2); CRP¼C-reactive protein (mg l 1); HCG¼beta-human
chorionic gonadotropin; IGCCCG¼ International Germ Cell Cancer Collaborative Group;
IQR¼ interquartile range; LDH¼ lactate dehydrogenase (U l 1); NLR¼ neutrophil-to-lym-
phocyte ratio; PLR¼platelet-to-lymphocyte ratio; SII¼ systemic immune-inflammation
index.
Table 2. Univariate Cox regression analysis
Overall survival
HR (95% CI) P-value









Haemoglobin (g l 1) 0.962 (0.942–0.982) o0.001
Platelets (103 per ml) 1.004 (1.000–1.009) 0.069
Leukocytes (103 per ml) 1.136 (1.14–1.565) o0.001
Neutrophils (103 per ml) 1.611 (1.23–2.105) o0.001
Lymphocytes (103 per ml) 0.497 (0.127–1.940) 0.31
CRP (mg l 1) 6.44 (2.04–20.29) 0.001
Albumin (g l1) 0.844 (0.742–0.961) 0.010
NLRa 73.1 (3.70–1442) 0.005
PLRa 8.42 (0.72–98.7) 0.090
SIIa 30.2 (3.00–304) 0.004
Abbreviations: CI¼ confidence interval; CRP¼C-reactive protein; HR¼ hazard ratio;
IGCCCG¼ International Germ Cell Cancer Collaborative Group; IQR¼ interquartile range;
NLR¼ neutrophils-to-lymphocytes ratio; PLR¼platelets-to-lymphocytes ratio; SII¼ systemic
immune-inflammation index.
aAfter log10 transformation: the HR thus corresponds to a 10-fold increase of the variable,
bold P-values indicate statistical significance.
Table 3. The incremental prognostic information of each
marker was assessed by performing separate multivariable
Cox regression analyses including each marker and the
IGCCCG risk groupings
Overall survival
HR (95% CI) P-value
IGCCCG risk groups (good/intermediate
vs poor risk)
0.142 (0.032–0.623) 0.010
Haemoglobin (g l 1) 0.983 (0.958–1.007) 0.17
IGCCCG risk groups (good/intermediate
vs poor risk)
7.26 (2.03–26.0) 0.002
Leukocytes (103 per ml) 1.27 (1.06–1.54) 0.011
IGCCCG risk groups (good/intermediate
vs poor risk)
0.180 (0.047–0.686) 0.012
Neutrophils (103 per ml) 1.47 (1.09–1.98) 0.011
IGCCCG risk groups (good/intermediate
vs poor risk)
0.117 (0.017–0.810) 0.030
CRP (mg l 1) 1.01 (1.00–1.02) 0.062
IGCCCG risk groups (good/intermediate
vs poor risk)
0.131–0.008–2.12) 0.15
Albumin (g l1) 0.981 (0.768–1.25) 0.88
IGCCCG risk groups (good/intermediate
vs poor risk)
0.130 (0.036–0.464) 0.002
NLRa 84.5 (2.2–3193) 0.017
IGCCCG risk groups (good/intermediate
vs poor risk)
0.161 (0.042–0.615) 0.008
SIIa 12.1 (1.17–126) 0.037
Abbreviations: CI¼ confidence interval; CRP¼C-reactive protein; HR¼ hazard ratio;
IGCCCG¼ International Germ Cell Cancer Collaborative Group; NLR¼ neutrophils-to-
lymphocytes ratio; SII¼ systemic immune-inflammation index.
aAfter log10 transformation: the HR thus corresponds to a 10-fold increase of the variable,
bold P-values indicate statistical significance.
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a closer follow-up schedule or an intensified treatment algorithm
for these patients. In the present investigation, we were able to
show, to the best of our knowledge for the first time, that different
markers of systemic inflammation (namely leukocytes, neutrophils,
NLR and SII) have the potential to improve prediction of oncologic
outcome in patients with metastatic GCT in addition to the well-
established IGCCCG classification system. Improved prediction of
oncologic outcome might impact the decision of what systemic
treatment a patient will receive and thus, might lead to more
personalised and eventually more effective treatment decision for
selected patients with metastatic GCT.
The IGCCCG risk classification has been shown to be an
independent predictor of oncologic outcome for patients with
metastatic GCT (International-Germ-Cell-Cancer-Collaborative-
Group, 1997). The classification system was published in 1997
and is based on multi-institutional data of patients treated between
1975 and 1990. Since then, improvements in diagnostics (mainly
imaging) but also novel treatment protocols and more standardised
follow-up regimens have been implemented into testis cancer care.
It is likely that these changes in disease management have an
impact on the validity of the ‘historical’ IGCCCG classification. An
update of the IGCCCG classification system using a more
contemporary patient cohort is currently in preparation (Collette
and Assele, 2017). This update is likely to more precisely predict
the oncologic outcome of contemporary patients with metastatic
GCT. In addition, it offers the opportunity to test new promising
variables such as novel biomarkers or information from genetic
testing and imaging studies, which might further improve risk
prediction traditionally based only on conventional clinico-
pathological parameters.
Cancer-related inflammation had initially been thought to be a
pure anti-tumoural response of the host system. However, it
became obvious that several immune mechanisms promote
tumour development and progression such that inflammation is
now regarded as one of the hallmarks of cancer (Grivennikov et al,
2010; Hanahan and Weinberg, 2011). For example, the innate
immune system, represented by, for example, circulating neutro-
phils is thought to have a tumour-promoting role. In contrast,
immune cells of the adaptive system (e.g., lymphocytes) represent
the anti-tumour system. Thus, the pro-tumour or anti-tumour
activity of the different immune cells determines whether high
levels of these cells predict a favourable or unfavourable prognosis.
Many of the exact underlying inflammatory mechanisms are still
incompletely understood, but it is known that they include the
supply of factors by immune cells and tumour cells (e.g., growth
factors, pro-inflammatory cytokines, angiogenic factors and
enzymes modifying the tumour microenvironment) (Hanahan
and Weinberg, 2011). For example, interleukin-6, which is
increased in patients with different neoplasms, is known to
upregulate the synthesis of acute phase proteins including CRP and
to downregulate the albumin production in the liver (Ohsugi, 2007;
Lippitz, 2013).
Given the role of inflammation in tumour biology, there is a
biological rationale for the use of inflammatory markers to predict
cancer outcome. It has been shown that the utility of inflammatory
markers varies between different tumours (Templeton et al,
2014b). If chronic inflammatory processes are the reason for
tumour development (e.g., in asbestosis-related mesothelioma),
inflammatory markers are known to be of particular value for
outcome prediction (Templeton et al, 2014b). In GCTs, inflam-
matory processes can also be detected (e.g., tumour infiltrating
lymphocytes as a typical feature of seminoma, (Emerson and
Ulbright, 2007)) indicating that inflammatory markers might be of
value for GCT. Furthermore, it has been shown that more
advanced and metastatic disease is often associated with higher
inflammatory markers that might be due to either prolonged
chronic inflammatory processes or simply a greater tumour burden
(Templeton et al, 2014b). Higher neutrophils and leukocytes where
also found in patients with brain, bone or visceral metastases in the
present investigation.
Systemic inflammatory markers are very attractive prognos-
ticators because they can easily be retrieved from routinely
performed, inexpensive blood tests. Single markers from CBCs
such as leukocytes, platelets and haemoglobin have been shown to
have prognostic potential for many malignant tumours (Manegold,
1998; Ishizuka et al, 2013; Hamai et al, 2014; Templeton et al,
2014a; Grimm et al, 2016). Non-CBC markers (e.g., CRP and
albumin) have also been found to be of prognostic utility in a
variety of malignancies (Forrest et al, 2003; Al Murri et al, 2006;
McMillan et al, 2007; Saito and Kihara, 2013; Dai et al, 2014;
Huang et al, 2015; Shrotriya et al, 2015). In the present
investigation, leukocytes and neutrophils remained significant
predictors of oncologic outcome besides the IGCCCG risk groups.
Besides these single-parameter markers, several ratios of
different parameters (e.g., NLR, PLR, SII) have been investigated.
These markers take the different pro-tumour and anti-tumour
activity of different immune cells into account, and thus, are
thought to better reflect the actual inflammatory response
associated with initiation and progression of a malignant tumour.
Neutrophils-to-lymphocytes-ratio is the most extensively investi-
gated ratio and has been shown to be a strong prognosticator in
many malignancies (Templeton et al, 2014a). The more recently
developed marker SII, a combination of NLR and PLR has also
been shown to predict oncologic outcome in several tumours
including GCT (Hu et al, 2014; Lolli et al, 2016; Chovanec et al,
2017). In the present investigation, both, NLR and SII remained
independent predictors of OS besides the IGCCCG risk groups.
There is most likely some redundancy and overlap between the
different inflammatory markers. Bhindi et al (2016) were able to
show that for patients with bladder cancer undergoing radical
cystectomy single CBC markers were outperformed by ratios of
different markers in terms of prediction of oncologic outcome. In
their investigation, which did not include the SII marker, NLR was
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Figure 1. Kaplan–Meier curves split by leukocyte count, neutrophil count, neutrophil-to-lymphocytes ratio (NLR) and systemic immune-
inflammation index (SII).
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(i.e., recurrence-free survival, cancer-specific survival and OS). In
the present investigation, we were not able to determine which
inflammatory marker or which combination of markers most
efficiently predicts oncologic outcome in combination with the
IGCCCG risk classification, due to our limited number of events. It
was not possible to test more than one systematic inflammatory
marker in the same multivariate analysis together with IGCCCG
risk groups. Thus, our analyses should rather be considered
exploratory than confirmatory. In addition, multiple testing may
lead to type I errors, which might overestimate the described
associations between inflammatory markers and oncologic out-
comes. However, multiple testing is justifiable in a hypothesis-
generating exploratory analysis. Hence, our results show that
inflammatory markers have the potential to improve prediction of
oncologic outcome, but ultimately, a larger data set is needed to
exactly determine which markers will be useful in clinical practice.
In conclusion, several systemic inflammatory markers, which
are available from routinely performed inexpensive blood tests,
demonstrated incremental prognostic information in addition to
the IGCCCG risk groups for patients with metastatic GCT
undergoing first-line chemotherapy. The planned IGCCCG update
might be an opportunity to elucidate which inflammatory markers
would ultimately possess the greatest potential to predict oncologic
outcomes besides the IGCCCG classification in this patient
population.
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